Innoviva, Inc 8-K/A, filed Oct 28, 2022
Innoviva, Inc. (INVA)
About this 8-K/A
Innoviva, Inc filed this 8-K/A on October 28, 2022, reporting on events of July 20, 2022.
Items reported
- Item 2.01: Completed an acquisition or sale of assets
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
(
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.01 Completion of Acquisition or Disposition of Assets
In the Current Report on Form 8-K filed by Innoviva, Inc. (the “Company”) on July 20, 2022 (the “Initial 8-K”), the Company reported the sale of 750 Class A Units and 750 Class C Units of Theravance Respiratory Company, LLC (the “Seller Equity”), pursuant to that certain Equity Purchase Agreement (the “Sale”) by and the Company, Innoviva TRC Holdings LLC, a Delaware limited liability company and wholly-owned subsidiary of Innoviva, and Royalty Pharma Investments 2019 ICAV (“Purchaser”), dated as of July 13, 2022, had closed, and the Seller Equity had been transferred to Purchaser.
The Company is filing this amendment (“Amendment No. 1”) in order to amend and supplement the Initial 8-K to include the historical and pro forma financial information required under Item 9.01 of Form 8-K with respect to the TRC Sale.
Item 9.01 Financial Statements and Exhibits
(b) Pro Forma Financial Information.
The following unaudited pro forma condensed combined financial information of the Company and certain assets acquired and liabilities assumed by the Company pursuant to the Acquisition are filed herewith as Exhibit 99.1 to this Amendment No. 1 and incorporated by reference into this Item 9.01(b):
| ● | Unaudited Pro Forma Condensed Consolidated Statement of Income for the Six Months Ended June 30, 2022. |
| ● | Unaudited Pro Forma Condensed Consolidated Statement of Income for the Year Ended December 31, 2021. |
| ● | Unaudited Pro Forma Condensed Consolidated Balance Sheet as of June 30, 2022 |
(d) Exhibits
| 99.1 | Unaudited Pro Forma Condensed Consolidated Financial Information |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 28, 2022 | INNOVIVA, INC. | |
| By: | /s/ Pavel Raifeld | |
| Pavel Raifeld | ||
| Chief Executive Officer | ||
EXHIBIT 99.1
INNOVIVA, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
On July 20, 2022, Innoviva TRC Holdings LLC (the “Seller”), a Delaware limited liability company and wholly-owned subsidiary of Innoviva, Inc. (the “Company”), completed the sale (the “Sale”) contemplated by the Equity Purchase Agreement (the “Purchase Agreement”) dated July 13, 2022, by and among the Company, the Seller and Royalty Pharma Investments 2019 ICAV (the “Buyer”), pursuant to which Seller agreed to sell its 750 Class A Units and 750 Class C Units of Theravance Respiratory Company, LLC (“TRC”) (the “Seller Equity”), representing all of the Seller’s 15% ownership in TRC, to the Buyer for an upfront cash payment of $281.9 million and a $50 million contingent sales-based milestone payment, on the terms and conditions set forth in the Purchase Agreement. Prior to the Sale, the Seller consolidated TRC under the variable interest model. The $281.9 million upfront cash payment consisted of: (i) $277.5 million paid by Buyer for the Seller Equity and (ii) $4.4 million cash distribution by TRC for the Seller’s portion of TRC’s cash balance prior to the Sale.
The Sale constitutes a significant disposition for the Company for purposes of Item 2.01 of Current Report on Form 8-K. As a result, the following unaudited pro forma condensed consolidated statements of income for the six months ended June 30, 2022 and for the year ended December 31, 2021 are presented as if the Sale had occurred on January 1, 2021. The following unaudited pro forma condensed consolidated balance sheet as of June 30, 2022 is presented as if the Sale had occurred on June 30, 2022.
The Sale was not contemplated as of June 30, 2022 and was not approved by the Seller’s Board of Directors until July 2022. The assets and liabilities associated with the Sale are not reflected as discontinued operations on the Company’s condensed consolidated statements of income and the condensed consolidated balance sheet.
The unaudited condensed consolidated pro forma financial statements are based on the historical financial statements prepared in accordance with U.S. generally accepted accounting principles and are presented based on information currently available. They are intended for informational purposes only and are not intended to represent the Company’s financial position or results of operations had the Sale and related events occurred on the dates indicated, or to project the Company’s financial performance for any future period.
The unaudited pro forma consolidated financial statements have been prepared in accordance with Regulation S-X Article 11, Pro Forma Financial Information, as amended by the final rule, Amendments to Financial Disclosures About Acquired and Disposed Businesses, as adopted by the U.S. Securities and Exchange Commission on May 20, 2020, and should be read in conjunction with the following: (i) the accompanying notes to the unaudited pro forma condensed consolidated financial information; (ii) the audited consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021; and (iii) the unaudited consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2022.
INNOVIVA, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
June 30, 2022
(In thousands)
| Historical | Transaction Accounting Adjustments | Pro Forma | |||||||||||||
| Assets | |||||||||||||||
| Current assets: | |||||||||||||||
| Cash and cash equivalents | $ | 283,580 | $ | 245,261 | (a) | $ | 474,957 | ||||||||
| (11,469 | ) | (b) | |||||||||||||
| (42,415 | ) | (c) | |||||||||||||
| Related party receivables from collaborative arrangements | 111,676 | (42,719 | ) | (d) | 68,957 | ||||||||||
| Prepaid expenses | 3,953 | — | 3,953 | ||||||||||||
| Other current assets | 1,119 | — | 1,119 | ||||||||||||
| Total current assets | 400,328 | 148,658 | 548,986 | ||||||||||||
| Property and equipment, net | 176 | — | 176 | ||||||||||||
| Equity and long-term investments | 494,097 | — | 494,097 | ||||||||||||
| Capitalized fees paid to a related party, net | 104,518 | — | 104,518 | ||||||||||||
| Right-of-use assets | 3,545 | — | 3,545 | ||||||||||||
| Goodwill | 5,544 | — | 5,544 | ||||||||||||
| Intangible assets | 105,000 | — | 105,000 | ||||||||||||
| Deferred tax assets, net | 23,274 | — | 23,274 | ||||||||||||
| Other assets | 1,157 | — | 1,157 | ||||||||||||
| Total assets | $ | 1,137,639 | $ | 148,658 | $ | 1,286,297 | |||||||||
| Liabilities and Stockholders’ Equity | |||||||||||||||
| Current liabilities: | |||||||||||||||
| Accounts payable | $ | 4,323 | — | $ | 4,323 | ||||||||||
| Accrued personnel-related expenses | 3,871 | — | 3,871 | ||||||||||||
| Accrued interest payable | 4,498 | — | 4,498 | ||||||||||||
| Accrued taxes | — | $ | 55,921 | (e) | 55,921 | ||||||||||
| Convertible subordinated notes due 2023, net of issuance costs | 96,072 | — | 96,072 | ||||||||||||
| Other accrued liabilities | 17,144 | (125 | ) | (c) | 17,019 | ||||||||||
| Total current liabilities | 125,908 | 55,796 | 181,704 | ||||||||||||
| Long-term debt, net of discount and issuance costs | 443,178 | — | 443,178 | ||||||||||||
| Lease liabilities, long-term | 3,091 | — | 3,091 | ||||||||||||
| Stockholders’ equity: | — | ||||||||||||||
| Preferred stock | — | — | — | ||||||||||||
| Common stock | 697 | — | 697 | ||||||||||||
| Treasury stock | (393,829 | ) | — | (393,829 | ) | ||||||||||
| Additional paid-in capital | 1,183,667 | — | 1,183,667 | ||||||||||||
| Accumulated deficit | (402,198 | ) | 207,844 | (f) | (160,876 | ) | |||||||||
| 33,478 | (g) | ||||||||||||||
| Total Innoviva stockholders’ equity | 388,337 | 241,322 | 629,659 | ||||||||||||
| Noncontrolling interest | 177,125 | (61,223 | ) | (h) | 28,665 | ||||||||||
| (11,469 | ) | (b) | |||||||||||||
| (42,290 | ) | (c) | |||||||||||||
| (33,478 | ) | (g) | |||||||||||||
| Total stockholders’ equity | 565,462 | 92,862 | 658,324 | ||||||||||||
| Total liabilities and stockholders’ equity | $ | 1,137,639 | $ | 148,658 | $ | 1,286,297 | |||||||||
INNOVIVA, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
Six Months Ended June 30, 2022
(In thousands, except per share data)
| Historical | Transaction Accounting Adjustments | Pro Forma | |||||||||||||
| Royalty revenue from a related party, net of amortization of capitalized fees paid to a related party | $ | 198,279 | $ | (72,029 | ) | (i) | $ | 126,250 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 19,722 | — | 19,722 | ||||||||||||
| General and administrative | 18,274 | (140 | ) | (i) | 18,134 | ||||||||||
| Total operating expenses | 37,996 | (140 | ) | 37,856 | |||||||||||
| Income from operations | 160,283 | (71,889 | ) | 88,394 | |||||||||||
| Interest and dividend income | 1,046 | — | 1,046 | ||||||||||||
| Other expense, net | (778 | ) | — | (778 | ) | ||||||||||
| Interest expense | (6,665 | ) | — | (6,665 | ) | ||||||||||
| Loss on debt extinguishment | (20,662 | ) | — | (20,662 | ) | ||||||||||
| Changes in fair values of equity and long-term investments, net | (68,011 | ) | — | (68,011 | ) | ||||||||||
| Income (loss) before income taxes | 65,213 | (71,889 | ) | (6,676 | ) | ||||||||||
| Income tax expense (benefit), net | 5,984 | (2,279 | ) | (m) | (3,705 | ) | |||||||||
| Net income (loss) | 59,229 | (69,610 | ) | (10,381 | ) | ||||||||||
| Net income (loss) attributable to noncontrolling interest | 42,517 | (53,396 | ) | (n) | (10,879 | ) | |||||||||
| Net income attributable to Innoviva stockholders | $ | 16,712 | $ | (16,214 | ) | $ | 498 | ||||||||
| Basic net income per share attributable to Innoviva stockholders | $ | 0.24 | $ | 0.01 | |||||||||||
| Diluted net income per share attributable to Innoviva stockholders | $ | 0.24 | $ | 0.01 | |||||||||||
| Shares used to compute Innoviva basic and diluted net income per share: | |||||||||||||||
| Shares used to compute basic net income per share | 69,594 | 69,594 | |||||||||||||
| Shares used to compute diluted net income per share | 94,692 | 69,671 | |||||||||||||
INNOVIVA, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
Year Ended December 31, 2021
(In thousands, except per share data)
| Historical | Transaction Accounting Adjustments | Pro Forma | |||||||||||||
| Royalty revenue from a related party, net of amortization of capitalized fees paid to a related party | $ | 391,866 | $ | (126,688 | ) | (i) | $ | 265,178 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 576 | — | 576 | ||||||||||||
| General and administrative | 16,187 | (3,480 | ) | (i) | 15,636 | ||||||||||
| 2,929 | (j) | ||||||||||||||
| Total operating expenses | 16,763 | (551 | ) | 16,212 | |||||||||||
| Gain on sale | — | 266,694 | (k) | 266,694 | |||||||||||
| Income from operations | 375,103 | 140,557 | 515,660 | ||||||||||||
| Interest and dividend income | 1,839 | — | 1,839 | ||||||||||||
| Other expense, net | (3,626 | ) | — | (3,626 | ) | ||||||||||
| Interest expense | (19,070 | ) | — | (19,070 | ) | ||||||||||
| Changes in fair values of equity and long-term investments, net | 91,030 | — | 91,030 | ||||||||||||
| Income before income taxes | 445,276 | 140,557 | 585,833 | ||||||||||||
| Income tax expense, net | 76,439 | 55,921 | (l) | 128,442 | |||||||||||
| (3,918 | ) | (m) | |||||||||||||
| Net income | 368,837 | 88,554 | 457,391 | ||||||||||||
| Net income (loss) attributable to noncontrolling interest | 102,983 | (103,012 | ) | (n) | (33,507 | ) | |||||||||
| (33,478 | ) | (o) | |||||||||||||
| Net income attributable to Innoviva stockholders | $ | 265,854 | $ | 225,044 | $ | 490,898 | |||||||||
| Basic net income per share attributable to Innoviva stockholders | $ | 3.24 | $ | 5.98 | |||||||||||
| Diluted net income per share attributable to Innoviva stockholders | $ | 2.87 | $ | 5.26 | |||||||||||
| Shares used to compute Innoviva basic and diluted net income per share: | |||||||||||||||
| Shares used to compute basic net income per share | 82,062 | 82,062 | |||||||||||||
| Shares used to compute diluted net income per share | 94,310 | 94,310 | |||||||||||||
INNOVIVA, INC.
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
| (1) | Basis of presentation |
The unaudited pro forma condensed consolidated financial statements are based on the historical consolidated financial statements of the Company as adjusted to give effect to the Sale. The unaudited pro forma condensed consolidated statements of income for the six months ended June 30, 2022 and the year ended December 31, 2021 give effect to the Sale as if it were completed on January 1, 2021. The unaudited pro forma condensed consolidated balance sheet as of June 30, 2022 gives effect to the Sale as if it were completed on June 30, 2022. The transaction accounting adjustments for the Sale consist of those necessary to account for the Sale.
| (2) | Pro Forma Adjustments |
The transaction accounting adjustments for the Sale are based upon available information and certain assumptions that management believes are reasonable.
| a. | Reflects estimated cash proceeds from the Seller Equity of $277.5 million less cash transferred to the Buyer of $29.3 million, and estimated transaction costs of $2.9 million. | |
| b. | Reflects quarterly cash distribution to noncontrolling interest holder on July 1, 2022. | |
| c. | Reflects TRC’s remaining cash balance that was attributable to noncontrolling interest holder, in the amount of $42.3 million, net of expense reimbursements of $0.1 million, and was made contemporaneously with the Sale and in accordance with the Purchase Agreement. | |
| d. | Reflects the royalty receivables transferred to the Buyer in the Sale. | |
| e. | Reflects estimated $55.9 million of current tax payable due to the recognition of the tax gain on the Sale and related transaction costs. | |
| f. | Reflects the adjustments to retained earnings as a result of the Sale calculated as follows: |
| Estimated proceeds of the Sale, net of payments to the Buyer and estimated transaction costs | $ | 245,261 | ||
| Royalty receivable transferred to the Buyer | (42,719 | ) | ||
| Noncontrolling interest | 61,223 | |||
| Pre-tax gain of the Sale offset by transaction costs (1) | 263,765 | |||
| Estimated tax expense on the gain of the Sale offset by estimated transaction costs | (55,921 | ) | ||
| After-tax gain of the Sale offset by transaction costs | $ | 207,844 |
(1) Reflects $266.7 million related to the gain on the Sale offset by $2.9 million of transaction costs.
| g. | Reflects the net impact of the transfer of TRC’s investments in certain private companies to the Company immediately prior to the Sale. | |
| h. | Reflects the noncontrolling interest being removed as a result of the Sale. | |
| i. | Reflects the elimination of TRC’s revenues and expenses for the six months ended June 30, 2022 and the year ended December 31, 2021 as a result of the Sale. | |
| j. | Reflects estimated transaction costs of $2.9 million. | |
| k. | Reflects the pre-tax gain of $266.7 million on the Sale. See (f) for further information. | |
| l. | Reflects the estimated tax expense of $55.9 million on the net gain of the Sale. See (f) for further information. | |
| m. | Reflects the estimated tax expense on the transaction related accounting adjustments, excluding the gain on the Sale offset by transaction costs. | |
| n. | Reflects the impact to noncontrolling interest as if the Sale had occurred on January 1, 2021. | |
| o. | Reflects the net impact to noncontrolling interest due to transfer of TRC’s investments in certain private companies to the Company prior to the Sale. |